$NBIO - Mr. Carrick continued, "Phase I demonstrated an excellent safety profile at various doses. Phase II will be focused on clinical outcomes, and we are taking no shortcuts." https://finance.yahoo.com/news/nascent-prepares-pivotal-phase-ii-120000620.html